Back to today’s briefing

Story perspectives

Tagrisso and Chemo Boost Survival for Lung Cancer Patients

7/21/2025

43 5

Summary

Story summary

AstraZeneca's Tagrisso, when paired with chemotherapy, has demonstrated remarkable survival benefits for patients battling advanced EGFR-mutated non-small cell lung cancer in the FLAURA2 Phase III trial. Approved in over 80 countries, this combination therapy solidifies Tagrisso's status as a leading treatment, while its manageable safety profile enhances patients' quality of life.

1 of 1

Story summary

AstraZeneca's Tagrisso, when paired with chemotherapy, has demonstrated remarkable survival benefits for patients battling advanced EGFR-mutated non-small cell lung cancer in the FLAURA2 Phase III trial. Approved in over 80 countries, this combination therapy solidifies Tagrisso's status as a leading treatment, while its manageable safety profile enhances patients' quality of life.